Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Novel Approaches Gain Ground in Diffuse Large B-Cell Lymphoma

February 28th 2020

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

Top NY GI Oncologists Spotlight Groundbreaking Research Efforts

February 27th 2020

Experts from Memorial Sloan Kettering Cancer Center and NYU Langone Health’s Perlmutter Cancer Center highlight some of the exciting research efforts being conducted at their respective institutions.

NICE Rejects Polatuzumab Vedotin Combo in Relapsed/Refractory DLBCL

February 27th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend polatuzumab vedotin plus rituximab and bendamustine for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma who cannot undergo hematopoietic stem cell transplant.

Breast Oncologists Aim to Address Key Unanswered Questions With Novel Research Efforts

February 26th 2020

Experts from Virginia Cancer Specialists, Georgetown University, Dana-Farber Cancer Institute, and Johns Hopkins Medicine to provide insight on some of the pivotal research being conducted at their respective institutions.

Randall Ruminates on Challenges With Treating Sarcomas in AYA Patients

February 25th 2020

R. Lor Randall, MD, FACS, highlights the specific challenges faced by adolescent and young adult patients with sarcomas, the importance of promoting awareness of this issue, and the resources available to improve outcomes in this population.

Agarwal Shares Insight on Promise With Cabozantinib/Atezolizumab in mCRPC

February 25th 2020

Neeraj Agarwal, MD, discusses the COSMIC-021 trial and shares the next steps for this research.

Efforts Expand for Targeting Rare Alterations in NSCLC

February 19th 2020

Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.

Janjigian Highlights Lessons Learned from 2020 Gastrointestinal Cancers Symposium

February 14th 2020

Yelena Janjigian, MD, highlights key updates from the 2020 Gastrointestinal Cancers Symposium and explained the impact that new data will have on clinical practice.

NICE Recommends Against Frontline Pembrolizumab/Axitinib in Advanced RCC

February 13th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend the combination of pembrolizumab and axitinib for use in treatment-naïve adult patients with advanced renal cell carcinoma.

NewYork-Presbyterian/Columbia University Breast Cancer Faculty Share 2020 Resolutions to Improve Patient Care

February 7th 2020

Faculty from NewYork-Presbyterian Hospital/Columbia University Irving Medical Center share their resolutions for the new year and the efforts being made to improve patient outcomes in practice.

CAR-T Paving New Path in Relapsed/Refractory Myeloma

February 7th 2020

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

ASCO Names Refinement of Surgical Treatment of Cancer as Advance of the Year

February 5th 2020

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Despite Advances, Unmet Need Remains in TNBC

February 3rd 2020

Kevin Kalinsky, MD, MS, highlights recent developments in triple-negative breast cancer, including the potential role of immunotherapy in the neoadjuvant setting.

FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC

January 30th 2020

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection for use in combination with erlotinib in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.

CMS Expands Coverage of NGS Diagnostic Tests for Germline Ovarian, Breast Cancers

January 29th 2020

The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.

Novel Strategies and Agents Emerge in AML Paradigm

January 25th 2020

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.

Three Biosimilars Entering US Oncology Market at Substantial Discounts

January 24th 2020

Three biosimilars—bevacizumab-bvzr (Zirabev), rituximab-pvvr (Ruxience), and trastuzumab-qyyp)—will become available in the United States at a substantial discount to their reference products.

NICE Cites Uncertainty in Deciding Against Larotrectinib in NTRK Fusion+ Solid Tumors

January 18th 2020

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Guiding Treatment Decisions in Newly Diagnosed Metastatic Melanoma

January 16th 2020

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

NICE Rejects Treatments for Head and Neck Cancer and AML

January 16th 2020

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.